StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH)

Investment analysts at StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report released on Sunday. The firm set a “hold” rating on the stock.

Separately, Alliance Global Partners dropped their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Up 2.0 %

NASDAQ AWH opened at $0.87 on Friday. The stock has a market capitalization of $10.83 million, a PE ratio of -0.60 and a beta of 1.47. Aspira Women’s Health has a 12-month low of $0.74 and a 12-month high of $6.01. The company has a 50 day moving average price of $0.91 and a two-hundred day moving average price of $1.73.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million during the quarter, compared to analyst estimates of $2.60 million. During the same period in the previous year, the firm posted ($0.28) EPS. As a group, equities analysts anticipate that Aspira Women’s Health will post -1.26 EPS for the current year.

Institutional Trading of Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its stake in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. Institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.